118 related articles for article (PubMed ID: 14676441)
1. Hepatocyte expressions in hepatocellular carcinomas, gastrointestinal neoplasms, and non-neoplastic gastrointestinal mucosa: its role as a diagnostic marker.
Lee HS; Kim WH; Kang GH
J Korean Med Sci; 2003 Dec; 18(6):842-8. PubMed ID: 14676441
[TBL] [Abstract][Full Text] [Related]
2. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma.
Xiao SY; Wang HL; Hart J; Fleming D; Beard MR
Am J Pathol; 2001 Oct; 159(4):1415-21. PubMed ID: 11583969
[TBL] [Abstract][Full Text] [Related]
3. Expression of RNA-binding protein LIN28 in classic gastric hepatoid carcinomas, gastric fetal type gastrointestinal adenocarcinomas, and hepatocellular carcinomas: An immunohistochemical study with comparison to SALL4, alpha-fetoprotein, glypican-3, and Hep Par1.
Zhao M; Sun L; Lai JZ; Shi H; Mei K; He X; Jin X; Lai J; Cao D
Pathol Res Pract; 2018 Oct; 214(10):1707-1712. PubMed ID: 30196987
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples.
Lugli A; Tornillo L; Mirlacher M; Bundi M; Sauter G; Terracciano LM
Am J Clin Pathol; 2004 Nov; 122(5):721-7. PubMed ID: 15491968
[TBL] [Abstract][Full Text] [Related]
5. The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma.
Karabork A; Kaygusuz G; Ekinci C
Pathol Res Pract; 2010 Aug; 206(8):572-7. PubMed ID: 20400233
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratin patterns of liver carcinomas induced by diethylnitrosamine in monkeys.
Lapis K; Sarosi I; Bocsi J; Thorgeirsson UP
Lab Invest; 1995 Jun; 72(6):748-59. PubMed ID: 7540236
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.
Chu PG; Ishizawa S; Wu E; Weiss LM
Am J Surg Pathol; 2002 Aug; 26(8):978-88. PubMed ID: 12170084
[TBL] [Abstract][Full Text] [Related]
8. Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival.
Mondada D; Bosman FT; Fontolliet C; Seelentag WK
Virchows Arch; 2006 Jan; 448(1):35-45. PubMed ID: 16220294
[TBL] [Abstract][Full Text] [Related]
9. Ectopeptidases are differentially expressed in hepatocellular carcinomas.
Röcken C; Carl-McGrath S; Gräntzdörffer I; Mantke R; Roessner A; Lendeckel U
Int J Oncol; 2004 Mar; 24(3):487-95. PubMed ID: 14767532
[TBL] [Abstract][Full Text] [Related]
10. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas.
Borscheri N; Roessner A; Röcken C
Am J Surg Pathol; 2001 Oct; 25(10):1297-303. PubMed ID: 11688465
[TBL] [Abstract][Full Text] [Related]
11. Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors.
Amarapurkar AD; Rege JD; Joshi AS; Vaiphei K; Amarapurkar DN
Indian J Pathol Microbiol; 2006 Jul; 49(3):341-4. PubMed ID: 17001880
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma.
Kakar S; Muir T; Murphy LM; Lloyd RV; Burgart LJ
Am J Clin Pathol; 2003 Mar; 119(3):361-6. PubMed ID: 12645337
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic significance of aquaporin-1 in liver tumors.
Mazal PR; Susani M; Wrba F; Haitel A
Hum Pathol; 2005 Nov; 36(11):1226-31. PubMed ID: 16260277
[TBL] [Abstract][Full Text] [Related]
14. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
[TBL] [Abstract][Full Text] [Related]
15. BSEP and MDR3: Useful Immunohistochemical Markers to Discriminate Hepatocellular Carcinomas From Intrahepatic Cholangiocarcinomas and Hepatoid Carcinomas.
Fujikura K; Yamasaki T; Otani K; Kanzawa M; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
Am J Surg Pathol; 2016 May; 40(5):689-96. PubMed ID: 26735860
[TBL] [Abstract][Full Text] [Related]
16. Hep par-1: a novel immunohistochemical marker for differentiating hepatocellular carcinoma from metastatic carcinoma.
Hanif R; Mansoor S
J Coll Physicians Surg Pak; 2014 Mar; 24(3):186-9. PubMed ID: 24613115
[TBL] [Abstract][Full Text] [Related]
17. C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study.
Nakopoulou L; Stefanaki K; Filaktopoulos D; Giannopoulou I
Histol Histopathol; 1994 Oct; 9(4):677-82. PubMed ID: 7894139
[TBL] [Abstract][Full Text] [Related]
18. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver.
Morrison C; Marsh W; Frankel WL
Mod Pathol; 2002 Dec; 15(12):1279-87. PubMed ID: 12481008
[TBL] [Abstract][Full Text] [Related]
19. Hep Par 1 in gastric and bowel carcinomas: an immunohistochemical study.
Villari D; Caruso R; Grosso M; Vitarelli E; Righi M; Barresi G
Pathology; 2002 Oct; 34(5):423-6. PubMed ID: 12408340
[TBL] [Abstract][Full Text] [Related]
20. Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms.
Shahid M; Mubeen A; Tse J; Kakar S; Bateman AC; Borger D; Rivera MN; Ting DT; Deshpande V
Am J Surg Pathol; 2015 Jan; 39(1):25-34. PubMed ID: 25353287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
